VivoSense, Inc., is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare research & delivery, clinical trials, and patient wellness. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense® software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. For more information visit www.vivosense.com. We are on Twitter. Follow us @vivosense.
The Digital Medicine Society (DiMe) is a global non-profit and the professional home for all members of the digital medicine community. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health.
The Digital Biomarkers & Digital Measurements Summit is back with a bang! Bringing you 2 full days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital biomarkers & digital measurements ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. We’ve got a lot to catch up on and this Summit has got you covered!
Starting with the differences between digital biomarkers, measurements and endpoints, through to commercialization, this Summit will provide you with a truly end-to-end learning experience. Learning is at the heart of the agenda and through a variety of dynamic formats, you will be able to accelerate your understanding of the industry in just two days.
Digital biomarkers and digital measurements have long been explored but with the recent changes to healthcare and pharma, there is greater interest than ever before in what they can offer. This Summit will help define this new wave of the industry through exclusive discussions with the movers and shakers, and this is your chance to be part of them.
The COVID-19 public health emergency shifted a number of protocols and operating plans for clinical research and care alike. As more trials and care shift to the home, convening folks working on these problems in a common summit will help us ensure that more high quality measures support patients at home.
Digital Biomarkers & Digital Measurements Summit is ideally timed to enable critical conversations between stakeholders enabling the progression of medicine toward a patient-oriented, decentralized, tech-enabled future.
The Digital Biomarkers & Digital Measurement Summit convenes experts from across the healthcare and clinical research paradigms to discuss the most pressing issues facing the field. If you have a remote patient monitoring strategy, or if you’re building one, you should be here.
The Digital Biomarkers event is a critical place to learn, evaluate, and “take inventory” in an industry that is the front door to enabling the promise of precision medicine. I’m particularly intrigued to learn about how innovators are thinking about the validation of digital biomarkers to be used as clinical endpoints, then how they can be embedded into digital therapeutics for real-world use.
2021 Speaker Faculty
Jennifer C. Goldsack co-founded and serves as the CEO of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. Jennifer’s research focuses on applied approaches to the safe, effective, and equitable use of digital technologies to improve health, healthcare, and health research. She is a member of the Roundtable on Genomics and Precision Health at the National Academies of Science, Engineering and Medicine and serves on the World Economic Forum Global Leadership Council on mental health.
Previously, Jennifer spent several years at the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by Duke University and the FDA. There, she led development and implementation of several projects within CTTI’s Digital Program and was the operational co-lead on the first randomized clinical trial using FDA’s Sentinel System.
Jennifer spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, she helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware.
Jennifer earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality. Jennifer is a retired athlete, formerly a Pan American Games Champion, Olympian, and World Championship silver medalist.
Dr. Cole Zanetti is the Senior Advisor for the National Veteran Health Administration’s Innovation Ecosystem; he also serves as the Chief Health Informatics Officer for the Ralph H. Johnson VA Health System in Charleston South Carolina. He is an Associate Professor and Director for the Digital Health Track at Rocky Vista University College of Osteopathic Medicine. He is a triple board-certified physician in Clinical Informatics, Family Medicine, and Preventive Medicine. He completed his residency training at Dartmouth. He was the recipient of the National Emerging Leader Award from the American Osteopathic Foundation and the Primary Care Innovation Award by the American College of Physicians. Dr. Zanetti earned his MPH at the Dartmouth Institute for Health Policy and Clinical Practice. He earned his Osteopathic Medical Degree from the Texas College of Osteopathic Medicine. He also holds a BA in Psychology from the University at Buffalo. He additionally earned a Certificate in Leadership, Organizing and Action from the John F. Kennedy School of Government at Harvard University.
Anders heads a business entity within Sony that provides connected solutions
leveraging 4G/5G IoT communication technology for application areas such as mobile
health and safety. The vision is to be a facilitator and front-runner for next-generation
digital biomarker solutions.
Anders has a background from the med tech industry and has worked in several major
companies, among them Hewlett-Packard, Siemens and HemoCue. Anders has also
experience from the telecom and cybersecurity industry where he has worked in
several start-up companies providing application platforms, application and consulting
since 2000. This includes companies like Advenica, Appium/Aepona, MIMT, Heyhop,
Bluelabs and moveAround.
Anders has held management functions within business development, R&D and
The Health Solution Division was established in 2019 as a result from an innovation
competition within Sony and is driven by Anders.
Carrie Northcott, PhD is a Director/ Project Lead within Digital Medicine and
Translational Imaging (DMTI), Early Clinical Development (ECD) at Pfizer. She
leads a driven and diverse team that is evaluating and validating the use of
wearable digital devices to more fully understand and characterize
physiological endpoints, such as quantitatively measuring night-time scratch
and sleep. Carrie has a diverse scientific background in Pharmacology,
Toxicology, and Physiology which provides unique insight into understanding
how these novel digital endpoints provide meaningful information to patients,
doctors and researchers to better treat and understand diseases.
Michelle Holko, PhD, PMP, is a strategic innovator working at the intersection of biology, technology, and security. She is currently a Principal Architect and Scientist at Google working as the technical lead with the Google Cloud healthcare and life sciences team. She also holds a PI appointment at the International Computer Science Institute (ICSI) at Berkeley, leading a research area at the intersection of biotech and cybersecurity. Prior to joining Google, she served in government as a Presidential Innovation Fellow (PIF), during which time she worked with the Department of Homeland Security’s (DHS) Cybersecurity and Infrastructure Security Agency (CISA), the Department of Defense (DoD) Chemical and Biological Defense Program (CBDP), the NIH’s All of Us Research Program, HHS BARDA, OSTP and NSC. Prior to joining the PIF program, she worked with DARPA and HHS BARDA, and was a fellow in the 2018 cohort of Johns Hopkins University’s Center for Health Security’s Emerging Leaders in Biosecurity Initiative. She has also served as a Staff Scientist at NIH’s NCBI, working with the primary data archives to promote re-use and re-analysis of biomedical research data. Dr. Holko’s technical expertise is in genomics and bioinformatics, and she has experience working on pandemic prevention and preparedness, infectious diseases, cancer, biosurveillance, biosecurity, data science, emerging technologies, health technologies, precision medicine, cybersecurity, and machine learning/artificial intelligence. Dr. Holko is an inclusive, empathetic leader, interested in building security into biotechnology and health innovations to promote innovations in biomedical research. She has spent her career leveraging technology to foster scientific discovery.
Dr. Abhishek Pratap leads the digital health & AI research group (www.aid4mental.health) at Krembil
Center for Neuroinformatics, CAMH (Canada’s largest mental health research hospital). His research
focuses on understanding the individualized real-world experience of mental health by developing
people-augmented digital health solutions and optimal ways for deploying technology in the real world
— what works for whom, when, and how long.
Before joining CAMH, Dr. Pratap was a Principal Scientist, Digital Health at Sage Bionetworks (A
Seattle-based non-profit). At Sage, he led the design & deployment of many real-world studies to
evaluate long-term disease trajectories in neurological and psychiatric disorders. Dr. Pratap has
collaborated with various stakeholders in the academia, pharma, and tech industry to assess empirical
challenges and potential solutions to help generate robust real-world evidence from RWD. Findings
from his research have extended the ongoing efforts to objectively evaluate the potential fit of
technology in psychiatry in augmenting episodic clinical evaluations with frequent monitoring of mental
health in the real world.
Dr. Pratap has a Ph.D. from the University of Washington in Biomedical Health Informatics specializing
in digital health. Dr. Pratap also holds additional faculty appointments at the Department of Psychiatry,
University of Toronto, Vector Institute, and University of Washington, Seattle. He is also a visiting fellow
at King’s College London, London.
Benjamin Vandendriessche is Chief Medical Officer at Byteflies, the Belgian-American company behind Sensor Dot, a powerful platform for 24/7 capture of medical insights to deliver care at home and augment clinical trials with real-world data. He is specialized in molecular biology, systems physiology, and data analytics for physiologic waveform and vital sign processing. He completed a PhD in Molecular Biology at Ghent University as an IWT Fellow, followed by a postdoc in Computer Science at Case Western Reserve University (CWRU) as a BAEF Fellow. He currently is an adjunct assistant professor at CWRU.
Siva is the President and Co-Founder of JOGO Health, a digital therapeutics company that uses wearable sensors and AI to treat chronic pain and neuromuscular conditions.
Siva has over 23 years of experience in healthcare. His previous venture, an AI based drug and vaccine safety monitoring platform was acquired by IQVIA, where he served as a global head and general manager for six years. Siva has two patents related to AI in healthcare. In 1998, Siva was recognized for uncovering two major internet security holes, which forever changed how users logged into Internet sites from public computers.
Siva has spoken at major healthcare conferences in 20+ countries.
Larsson Omberg is a VP at Sage Bionetworks and head of Sage’s Digital Health Research Group. He oversees a research agenda that focuses both on genomics and participant centered research where data is being collected using remote sensors and mobile phones. The group focuses heavily on using open and team based science to get a large number of external partners to collaborate on data intensive problems. Dr. Omberg has a background in computational biology and has been developing computational methods for disease modeling, populatione genetics and digital biomarkers. Dr Omberg obtained a MSc in Engineering Physics from the Royal Institute of Technology in Stockholm Sweden and a PhD. from the University of Texas at Austin in Physics before performing a postdoctoral fellowship in Computational Biology and Biostatistics at Cornell University.
Sarah Ernst has 10+ years working in the healthcare and digital health, and she has spent the last 4 years at Sanofi working on accelerating digital innovation. In her work at Sanofi, Sarah has worked closely to accelerate the adoption of and impact of both digital biomarkers and digital therapeutics across Sanofi’s portfolio. Prior to her time at Sanofi, Sarah work at PatientsLikeMe, Imprivata, and the Advisory Board Company focused on improving patient care and patient experience by leveraging digital technologies. Sarah has her Masters in Engineering Management from Tufts University, and Bachelors in Neuroscience from the University of Pennsylvania
Dexter Hadley, MD/PhD has expertise is in translating big data into precision medicine and digital health. His research generates, annotates, and ultimately reasons over large multi-modal data stores to develop clinical intelligence, identify novel biomarkers and potential therapeutics for disease. He earned his PhD in genomics and computational biology while at medical school at PENN, and he trained in clinical pathology while at residency at Stanford. He first became faculty at University of California San Francisco where he was won various grant funding for developing deep learning methods in medicine including over $5M from NIH. His contributions have yielded well over 60 peer reviewed publications. Dr. Hadley is the Founding Chief of AI at UCF College of Medicine and he will introduce his vision for Community Driven AI and share how his team is building a community of patients, clinicians, and data scientists that is needed to make this concept a reality.
Krishna is a physician-scientist, business oriented R&D leader with a wealth of U.S. and global life science industry experience in Medical affairs, Clinical development, academic research, and pharmacovigilance across multiple therapeutic categories. A collaborative and outcomes oriented leader, Krishna’s efforts have contributed to revenue growth through innovation and pipeline development, Rx to OTC Switch, clinical trial design and execution, medical affairs, scientific engagement and stakeholder outreach. Krishna has also successfully managed several FDA and international health authority submissions.
Krishna currently serves as Senior Clinical Lead within the Motion Biosensors Group at Philips Healthcare with global responsibility for ensuring scientific accuracy and value in various external facing engagements, scientific strategy, innovation, clinical development, algorithm validation, FDA engagement and interactions, and streamlining several commercial and sales scientific initiatives. Prior to joining Philips HealthCare, Krishna served in various roles at Merck and Bayer including Global Medical Strategic Director for upper respiratory, switch categories, white space, and women’s health portfolio, Clinical Development lead, and Pharmacovigilance officer. Earlier in her career, Krishna was also a medical writer with Care Management International.
Krishna earned her PhD in neuropharmacology from Southern Illinois University School of Medicine in Carbondale. Prior to this, Krishna also earned her Doctor of Medicine (MD) degree in Family Medicine from Bombay University in India. She has held various research positions at the Johns Hopkins University and University of Virginia in areas of neurodegenerative disorders and cardiovascular research.
Andy Coravos (@andreacoravos) is the CEO/co-founder of HumanFirst FKA Elektra Labs, building a digital medicine platform focusing on digital biomarkers for decentralized clinical trials. Formerly, she served as an Entrepreneur in Residence at the FDA working in the Digital Health Unit (DHU). She serves on the Board of the Digital Medicine Society (DiMe), and she’s an advisor to the Biohacking Village at DEF CON.
Everett leads the commercial organization at Cognito Therapeutics, a clinical-stage company developing a pipeline of disease-modifying therapeutics addressing novel neuro-electrical targets that have proven pathologies in neurodegenerative disorders, including Alzheimer’s disease. Prior to Cognito, Everett held the position of Chief Commercial Officer at AppliedVR, and has also previously served in executive leadership roles at leading digital therapeutic, pharmaceutical, and biotech companies. Everett currently serves on the board of the Digital Therapeutics Alliance.
Jessica Robin is the Director of Clinical Research at Winterlight Labs, leading the research and development of speech-based digital measures. Jessica has a PhD in cognitive neuroscience from the University of Toronto, and over ten years experience conducting behavioural and neuroscientific research on topics including cognition, neurodegenerative disease and psycholinguistics.
Ariel Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices in clinical studies across the organization. She was previously a Senior Clinical Data Scientist at Biogen, the algorithm team lead at MC10, and a senior research scientist at BioSensics. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and a BE from Dartmouth College. She serves on the Strategic Advisory Board of the DiMe Society.
To provide you with the very best virtual experience, the Digital Biomarkers & Digital Measurements Summit will be hosted on Hopin, a world-class purpose-built platform for exceptional events.
The benefits of virtual are endless! For starters, no more wondering who is in the room! View and message the entire attendee list, or reach out to any attendee through their connected LinkedIn profiles. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning! Through an engaging and connected live agenda, you can interact directly with the speakers, through Q&A, polls, interactive panel discussions, and more. And with recordings available for six months post-event, you won’t miss out on any of the exclusive content, no matter your schedule.
Imagine the possibilities for networking and learning!
Partner with Us
The Digital Biomarkers & Digital Measurements Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the senior R&D exec’s from across digital health, pharma, healthcare, investors and beyond.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at The Digital Biomarkers & Digital Measurements Summit.
Register for the Event
For pricing and booking options please click the button to go to the registration page.